News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MicroMass Launches Clinical Trial To Test Efficacy Of New App For Helping Patients With Type 2 Diabetes Meet HbA1c Targets



7/17/2014 10:23:07 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CARY, N.C.--(BUSINESS WIRE)--True to its 20-year experience in shaping human health behavior and demonstrating evidence-based outcomes, MicroMass Communications has embarked on a pre-launch clinical trial to determine if a newly developed mobile app can help people with Type 2 diabetes manage the disease more effectively in their everyday lives.

Partnering with employer groups and health systems in North Carolina, the MicroMass trial, titled the PROMISE in Diabetes Research Study, will monitor participants over a six-month period to determine if the behavior-change techniques featured in the app help patients meet their HbA1c targets. Through a simple blood test, HbA1c, or glycated hemoglobin, shows a person's average level of blood sugar over the previous three months, indicating how effectively that individual's diabetes is being controlled.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES